/PRNewswire/ Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive.
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models.
Actym Therapeutics Announces Significant Expansion of Senior Leadership streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.